Abstract:Importance: The population prevalence of cardiac transthyretin amyloidosis (ATTR) caused by pathogenic variation in the TTR gene (vATTR) is unknown. Objective: To estimate the population prevalence of disease-causing TTR variants and evaluate associated phenotypes and outcomes. Design, setting, and participants: This population-based cohort study analyzed UK Biobank (UKB) participants with whole-exome sequencing, electrocardiogram, and cardiovascular magnetic resonance data. Participants were enrolled from 2006 to 2010, with a median follow-up of 12 (IQR, 11-13) years (cutoff date for the analysis, March 12, 2024). Sixty-two candidate TTR variants were extracted based on rarity (minor allele frequency ≤0.0001) and/or previously described associations with amyloidosis if more frequent. Exposure: Carrier status for TTR variants. Main outcomes and measures: Associations of TTR carrier status with vATTR prevalence and cardiovascular imaging and electrocardiogram traits were explored using descriptive statistics. Associations between TTR carrier status and atrial fibrillation, conduction disease, heart failure, and all-cause mortality were evaluated using adjusted Cox proportional hazards models. Genotypic and diagnostic concordance was examined using International Statistical Classification of Diseases, Tenth Revision codes from the hospital record. Results: The overall cohort included 469 789 UKB participants (mean [SD] age, 56.5 [8.1] years; 54.2% female and 45.8% male). A likely pathogenic/pathogenic (LP/P) TTR variant was detected in 473 (0.1%) participants, with Val142Ile being the most prevalent (367 [77.6%]); 91 individuals (0.02%) were carriers of a variant of unknown significance . The overall prevalence of LP/P variants was 0.02% (105 of 444 243) in participants with European ancestry and 4.3% (321 of 7533) in participants with African ancestry. The LP/P variants were associated with higher left ventricular mass indexed to body surface area (β = 4.66; 95% CI, 1.87-7.44), and Val142Ile was associated with a longer PR interval (β = 18.34; 95% CI, 5.41-31.27). The LP/P carrier status was associated with a higher risk of heart failure (hazard ratio [HR], 2.68; 95% CI, 1.75-4.12) and conduction disease (HR, 1.88; 95% CI, 1.25-2.83). Higher all-cause mortality risk was observed for non-Val142Ile LP/P variants (HR, 1.98; 95% CI, 1.06-3.67). Thirteen participants (2.8%) with LP/P variants had diagnostic codes compatible with cardiac or neurologic amyloidosis. Variants of unknown significance were not associated with outcomes. Conclusions and relevance: This study found that approximately 1 in 1000 UKB participants were LP/P TTR variant carriers, exceeding previously reported prevalence. The findings emphasize the need for clinical vigilance in identifying individuals at risk of developing vATTR and associated poor outcomes.

Clinical spectrum of Transthyretin amyloidogenic mutations among diverse population origins

Clinical and biochemical characterization of asymptomatic carriers and symptomatic patients with hereditary transthyretin amyloidosis caused by TTR V30L mutation

Prevalence, Characteristics and Outcomes of Older Patients with Hereditary versus Wild‐Type Transthyretin Amyloid Cardiomyopathy

Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre

Transthyretin mutagenesis: impact on amyloidogenesis and disease

Hereditary Transthyretin Amyloidosis in Eight Chinese Families.

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy

Transthyretin-Related Hereditary Amyloidosis in a Chinese Family with TTR Y114C Mutation

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)

A Baseline Report of the First 3167 Participants

Rare Variant of Hereditary Amyloid Transthyretin Cardiomyopathy Secondary to Ser97Tyr Mutation

Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population

Clinical and Biochemical Characterization of Hereditary Transthyretin Amyloidosis Caused by E61K Mutation

A Study of Familial Amyloid Polyneuropathy Induced by the TTR Val30Leu Mutation in China

Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis

Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China

Characterization of Transthyretin Mutation G47V Associated with Hereditary Cardiac Amyloidosis

New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis

Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations

Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variability